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ABSTRACT 
Durable suppression of replication of the human immunodeficiency virus 
(HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which 
patients can easily adhere. Combination of two NRTIs and one NNRTI is the best 
first line regimen in treating retroviral disease (RVD) as compared to combinations of 
other groups. Tenofovir and Zidovudine are the two drugs that mostly use as one of 
NNRTIs in combination with either Lamivudine or Emtricitabine. Review of previous 
literature had shown that there were conflicting data on the superiority of either 
regime based on virologic and immunologic response. A local, retrospective 
observational cohort study was conducted to evaluate the virological response 
(primary endpoint), immunological response and the safety profile between TDF and 
AZT regimens. A total of 154 ART-nai've samples from HTAR and HSB were 
recruited. No statistically significant differences were observed in HIV RNA 
suppression at 24 weeks and 48 weeks (p = 0.407 and p = 0.521, respectively). Mean 
difference in CD4 increments were also not significant (p = 0.54, 95% CI -59.97, 
31.83 at week 24; p = 0.68, 95% CI -51.41, 33.59 at week 48). However, AZT was 
found with more adverse events that leads to discontinuation (p-value <0.001). There 
were two cases of virological failure in TDF group but the association was not 
significant (p = 0.497). Only education level was identified as predictor of therapy 
effectiveness. Although there was no significant difference in virological and 
immunological responses, TDF still has advantage over AZT because of its better 
safety profile. 
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